Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets (Parentheticals)

v3.24.0.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Deferred tax assets ($1.1 million and $1.0 million attributable to VIEs as of December 31, 2023 and 2022) $ 1,031,648 $ 11,928,152
Payroll liabilities attributable to VIEs 3,485,744 2,030,510
Deferred revenue from company clinics attributable to VIE 2,516,554 2,468,601
Liabilities to be disposed of ($3.6 million attributable to VIEs as of December 31, 2023) $ 13,831,863 $ 0
Series A preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Series A preferred stock, shares authorized (in shares) 50,000 50,000
Series A preferred stock, shares issued (in shares) 0 0
Series A preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, shares issued (in shares) 14,783,757 14,560,353
Common stock, shares outstanding (in shares) 14,751,633 14,528,487
Treasury stock, shares (in shares) 32,124 31,866
Variable Interest Entity, Primary Beneficiary    
Deferred tax assets ($1.1 million and $1.0 million attributable to VIEs as of December 31, 2023 and 2022) $ 1,100,000 $ 1,000,000.0
Payroll liabilities attributable to VIEs 700,000 600,000
Deferred revenue from company clinics attributable to VIE 1,600,000 $ 4,700,000
Liabilities to be disposed of ($3.6 million attributable to VIEs as of December 31, 2023) $ 3,600,000